Advanced search
Publication Cover
New Genetics and Society
Critical Studies of Contemporary Biosciences
Volume 26, 2007 - Issue 3
Submit an article Journal homepage
187
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Lay perspective on pharmacogenetics and its application to future drug treatment: a Danish quantitative survey

Louise Fuks NielsenDepartment of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, University of Copenhagen, Faculty of Pharmaceutical Sciences,, Copenhagen, Denmark
&
Claus MøldrupDepartment of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, University of Copenhagen, Faculty of Pharmaceutical Sciences,, Copenhagen, DenmarkView further author information
Pages 309-324 | Published online: 08 Jan 2008

References

  • Almarsdóttir, A. B., et al., 2005. A lay prescription for tailor-made drugs-focus group reflections on pharmacogenomics, Health Policy 71 (2005), pp. 233–41.
  • Andersen, I., 1999. Den skinbarlige virkelighed [The Naked Truth, in Danish], . Copenhagen: Samfundslitteratur; 1999.
  • Andreasen, J., 2003. For dyrt at udvikle nye lægemidler [Development of new drugs is too expensive, in Danish], Ugeskr.Læger 165 (19) (2003), pp. 1959–60.
  • Bates, B. R., et al., 2004. Evaluating direct-to-consumer marketing of race-based pharmacogenomics: a focus group study of public understandings of applied genomic medication, Journal of Health Communication 9 (6) (2004), pp. 541–59.
  • Condit, C., 2001. What is ‘public opinion’ about genetics?, Nature Reviews Genetics 2 (10) (2001), pp. 811–15.
  • Danmarks, Statistik, 2005. Statistikbanken, (2005), available at www.statistikbanken.dk (accessed 5 May 2005).
  • Henneman, L., et al., 2004. Public experiences, knowledge and expectations about medical genetics and use of genetic information, Community Genetics 7 (2004), pp. 33–43.
  • Henneman, L. F., et al., 2006. Public attitudes toward genetic testing: perceived benefits and objections, Genetic Testing 10 (2006), pp. 139–45.
  • Kollek, R. etal., 2006. Pharmacogenetics, adverse drug reactions and public health, Community Genetics 9 (1) (2006), pp. 50–4.
  • Kristensen, F. B., 2001. Metodehåndbog for Medicinsk Teknologivurdering (Handbook in Medical Technology Assessmentin Danish). Copenhagen: Statens Institut for Medicinsk Teknologivurdering; 2001.
  • Lazarou, J. etal., 1998. Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies, JAMA 279 (1998), pp. 1200–05.
  • Lesko, L. J., and Woodcock, J., 2004. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective, Nature Reviews Drug Discovery 3 (2004), pp. 763–9.
  • March, R. etal., 2001. Pharmacogenetics—legal, ethical and regulatory considerations, Pharmacogenomics 2 (4) (2001), pp. 317–27.
  • Møldrup, C., 2001. Ethical, social and legal implications of pharmacogenomics—a critical review, Community Genetics 4 (2001), pp. 204–14.
  • Møldrup, C., 2005. The prospects and bioethical dimensions of expanding the meaning of pharmacogenomics to compass individualized pharmacotherapy, Personalized Medicine 2 (2005), pp. 168–9.
  • Nielsen, L. F., and Møldrup, C., 2006. Lay perspective on pharmacogenomics, Personalized Medicine 3 (2006), pp. 311–16.
  • Nuffield Council on Bioethics, 2003. Pharmacogenetics: Ethical Issues. London: Nuffield Council on Bioethics; 2003.
  • Peakman, T., and Arlington, S., 2000. Putting the code to work: the promise of pharmacogenetics and pharmacogenomics, Drug Discovery World 2 (1) (2000), pp. 35–40.
  • Schmedders, M. etal., 2003. Individualized pharmacogenetic therapy: a critical analysis, Community Genetics 6 (2) (2003), pp. 114–19.
  • Shaw, J. S., and Bassi, K. L., 2001. Lay attitudes toward genetic testing for susceptibility to inherited diseases, Journal of Health Psychology 6 (4) (2001), pp. 405–23.
  • Soo-Jin, S. L., 2003. Race, distributive justice and the promise of pharmacogenomics: ethical considerations, American Journal of Pharmacogenomics 3 (6) (2003), pp. 385–92.
  • Vaszar, L. T., et al., 2003. Privacy issues in personalized medicine, Pharmacogenetics 4 (2) (2003), pp. 107–12.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.